6MD.F MEDACTA GROUP S.A. SF-,10
- Market cap
- EUR 2.37B
- P/E
- 30.7x
- P/B
- 4.91x
- ROE
- 20.9%
- Dividend yield
- 0.62%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6MD.F undervalued?
Graham number6MD.F trades 159.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MEDACTA GROUP S.A. SF-,10 fundamental analysis
No fundamental analysis for MEDACTA GROUP S.A. SF-,10 yet.
MEDACTA GROUP S.A. SF-,10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MEDACTA GROUP S.A. SF-,10
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Full company profileMEDACTA GROUP S.A. SF-,10 financial statements
MEDACTA GROUP S.A. SF-,10 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 363M | 437M | 511M | 591M | 684M |
| Gross Profit | 261M | 305M | 348M | 399M | 459M |
| Operating Income | 58.8M | 61.5M | 74.4M | 90.8M | 111M |
| EBITDA | - | 109M | 123M | 161M | 197M |
| Net Income | 51.5M | 46.2M | 47.4M | 72.9M | 95.5M |
| EPS | 2.58 | 2.32 | 2.38 | 3.66 | 4.79 |
| Balance Sheet | |||||
| Total Assets | 489M | 584M | 696M | 792M | 918M |
| Total Liabilities | 263M | 310M | 366M | 413M | 461M |
| Shareholders' Equity | 226M | 275M | 330M | 380M | 457M |
| Cash & Short-term Investments | 20.4M | 32.3M | 20.8M | 31.6M | 33.2M |
| Cash Flow | |||||
| Operating Cash Flow | 54.1M | 73.5M | 75.1M | 107M | 153M |
| Capital Expenditure | 54.6M | 71.3M | 82.2M | 105M | 143M |
| Free Cash Flow | -557K | 2.25M | -7.09M | 2.45M | 9.55M |
| Ratios | |||||
| ROE | 22.8% | 16.8% | 14.4% | 19.2% | 20.9% |
| ROA | 10.5% | 7.9% | 6.8% | 9.2% | 10.4% |
| Net Profit Margin | 14.2% | 10.6% | 9.3% | 12.3% | 14.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MEDACTA GROUP S.A. SF-,10 dividends
- Dividend yield
- 0.62%
- Forward dividend
- 1.20 EUR
- Payout ratio
- 15.4%
- Ex-dividend date
- May 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 14.7M | 0.74 | 15.4% |
| 2024 | EUR 11.2M | 0.56 | 15.4% |
| 2023 | EUR 11.1M | 0.55 | 23.3% |
| 2022 | EUR 10.4M | 0.52 | 22.5% |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns MEDACTA GROUP S.A. SF-,10
- Insiders 69.66%
- Institutions 13.87%
- Public & others 16.47%
- Shares outstanding 19.9M
- Free float 6.03M
MEDACTA GROUP S.A. SF-,10 company profile
- Company name
- MEDACTA GROUP S.A. SF-,10
- Ticker
- 6MD.F
- ISIN
- CH0468525222
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,273
- Fiscal year end
- December
- Address
- Strada Regina, 34, Castel San Pietro, Switzerland, 6874
- Phone
- 41 91 696 60 60
- Website
- medacta.com
About MEDACTA GROUP S.A. SF-,10
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
MEDACTA GROUP S.A. SF-,10 management
10- Dr. Alberto SiccardiFounder & Non Executive Chairman · born 1944
- Dr. Francesco SiccardiChief Executive Officer · born 1977
- Mr. Corrado FarsettaChief Financial Officer · born 1968
- Mr. Asif HussainChief People Officer · born 1971
- Mr. Alessandro SiccardiChief Supply Chain Officer · born 1986
- Filippo CappelliHead of IT
- Mr. Giovanni Niccolo GalliChief Commercial Officer · born 1976
- Mr. Massimiliano BernardoniChief Innovation Officer · born 1973
- Donato CortesiSecretary of the Board
- Antonio Di BrinoGroup Vice President of Finance & Tax